Personalized medicine can be seen as a continuously developing approach to tailoring treatments according to the individual characteristics of a patient. In some way, medicine has always been personalized. During the last decade, however, scientific and technological progress have made truly personalized healthcare increasingly become reality. Today’s personalized medicine involves targeted therapies and diagnostic tests. The development of targeted agents represents a major investment opportunity to pharmaceutical companies, which have been facing the need to diversify their business due to an increasingly challenging market place. By investing into the development of personalized therapies, pharmaceutical companies mitigate a major part of the risks posed by factors such as patent expiries or generic competition. Viewing upon personalized medicine from different perspectives points out the multi-causality of its emergence. Research efforts and business diversification have been two main driving forces; they do supplement each other, however, are not jointly exhaustive in explaining the emergence of this approach. Especially in the future, a number of further stakeholders will impact the evolution of personalized medicine.
References
[1]
President’s Council of Advisors on Science and Technology. Priorities for Personalized Medicine. Available online: http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast_report_v2.pdf (accessed on 3 June 2012).
[2]
Shaw, A.T. The Crizotinib Story: From Target to FDA Approval and Beyond. Available online: http://www.informedicalcme.com/lucatoday/crizotinib-story-from-target-to-fda-approval/ (accessed on10 August 2012).
[3]
Merla, A.; Goel, S. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: A systematic review. Chemother. Res. Pract. 2012, doi:10.1155/2012/387172.
[4]
Sharma, A.; Shah, S.R.; Illum, H.; Dowell, J. Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies. Drugs 2012, doi:10.2165/11640870-000000000-00000.
[5]
Canestaro, W.J.; Martell, L.A.; Wassman, E.R.; Schatzberg, R. Healthcare payers: A gate or a translational bridge to personalized medicine. Pers. Med. 2010, 9, 73–84.
[6]
The Age of Personalized Medicine: What is Personalized Medicine? Available online: http://www.ageofpersonalizedmedicine.org/what_is_personalized_medicine/ (accessed on 11 June 2012).
[7]
Collins, F.S. The Language of Life, DNA and the Revolution in Personalized Medicine; HarperCollins: New York, NY, USA, 2010; p. 58.
[8]
Salari, K.; Watkins, H.; Ashley, E.A. Personalized medicine: Hope or hype? Eur. Heart J. 2012, doi:10.1093/eurheartj/ehs112.
[9]
Madhur, M.S.; Riaz, K.; Dreisbach, A.W.; Harrison, D.G. Hypertension. Available online: http://emedicine.medscape.com/article/241381-overview (accessed on 20 November 2012).
[10]
Self, T.H.; Wallace, J.L.; Soberman, J.E. Cardioselective Beta-blocker treatment of hypertension in patients with asthma: When do benefits outweigh risks? J. Asthma. 2012, 49, 947–951, doi:10.3109/02770903.2012.719252.
[11]
Toh, S.; Reichman, M.E.; Houstoun, M.; Ross Southworth, M.; Ding, X.; Hernandez, A.F.; Levenson, M.; Li, L.; McCloskey, C.; Shoaibi, A.; et al. Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. Arch. Intern. Med. 2012, 15, 1–8.
[12]
Jain, K.K. Textbook of Personalized Medicine; Springer: New York, NY, USA, 2009.
[13]
Personalized Medicine Coalition (PMC). The Case of Personalized Medicine. Available online: http://www.personalizedmedicinecoalition.org/sites/default/files/files/Case_for_PM_3rd_edition.pdf (accessed on 27 May 2012).
[14]
What is Personalized Medicine? Available online: http://www.dukepersonalizedmedicine.org/what_is_personalized_medicine (accessed on 11 June 2012).
[15]
The Boston Consulting Group. Medizinische Biotechnologie in Deutschland 2011. Available online: http://www.vfa-bio.de/download/bcg-report-2011-broschuere.pdf (accessed on 30 May 2012).
[16]
Simmons, L.A.; Dinan, M.A.; Robinson, T.J.; Snyderman, R. Personalized medicine is more than genomic medicine: Confusion over terminology impedes progress towards personalized healthcare. Pers. Med. 2012, 9, 85–91, doi:10.2217/pme.11.86.
Tran, B.; Dancey, J.E.; Kamel-Reid, S.; McPherson, J.D.; Bedard, P.L.; Brown, A.M.; Zhang, T.; Shaw, P.; Onetto, N.; Stein, L.; et al. Cancer Genomics: Technology, Discovery, and Translation. J. Clin. Oncol. 2012, 30, 647–660.
[19]
Kampen, K.R. The discovery and early understanding of leukemia. Leuk. Res. 2012, 36, 6–13, doi:10.1016/j.leukres.2011.09.028.
[20]
Ferdinand, R.; Mitchell, S.A.; Batson, S.; Tumur, I. Treatments for chronic myeloid leukemia: A qualitative systematic review. J. Blood Med. 2012, 3, 51–76.
[21]
Breccia, M.; Alimena, G. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages. Cancer Lett. 2012, 322, 127–132, doi:10.1016/j.canlet.2012.03.021.
[22]
Blay, J.Y.; von Mehren, M. Nilotinib: A novel, selective tyrosine kinase inhibitor. Semin. Oncol. 2011, 38, S3–S9.
[23]
Gora-Tybor, J. Emerging therapies in chronic myeloid leukemia. Curr. Cancer Drug Targets 2012, 12, 458–470, doi:10.2174/156800912800673202.
[24]
Roland Berger Strategy Consultants. Fight or flight? Diversification vs. Rx-focus in big pharma’s quest for sustained growth. Available online: http://www.rolandberger.com/media/pdf/Roland_Berger_Fight_or_flight_Shortversion_20101025.pdf (accessed on 1 March 2012).
[25]
Cantrell, R. Outpacing the Competition: Patent-based Business Strategy; John Wiley and Sons: Hoboken, NJ, USA, 2009.
[26]
Jaruzelski, B.; Dehoff, K. The Global Innovation 1000: How the Top Innovators Keep Winning. Available online: http://www.booz.com/media/file/sb61_preprint_Global-Innov1000-10408.pdf (accessed on 2 June 2011).
[27]
March, R. Delivering on the promise of personalized healthcare. Pers. Med. 2010, 7, 327–337, doi:10.2217/pme.10.17.
[28]
Personalized Medicine Coalition (PMC). The Case for Personalized Medicine: All about Personalized Medicine. Available online: http://www.personalizedmedicinecoalition.org/about/about-personalized-medicine/the-case-for-personalized-medicine (accessed on 20 August 2012).
[29]
Lenz, C.; Girek, D.; Schmitt, D. Advancing health technology assessment (HTA) and reimbursement processes to promote access to personalized medicine. J. Pharmacol. Ther. 2011, 5, 150–152.
[30]
Miller, I.; Pothier, K.; Dunn, M. Advocacy in personalized medicine: A developing strength in a complex space. Pers. Med. 2010, 7, 179–186, doi:10.2217/pme.10.2.
[31]
Moch, H.; Blank, P.R.; Dietel, M.; Elmberger, G.; Kerr, K.M.; Palacios, J.; Penault-Llorca, F.; Rossi, G.; Szucs, T.D. Personalized cancer medicine and the future of pathology. Virchows Arch. 2012, 460, 3–8, doi:10.1007/s00428-011-1179-6.
[32]
Korn, D. Interview: A perspective on personalized medicine: Dr. David Korn. Pers. Med. 2012, 9, 259–263, doi:10.2217/pme.11.71.
[33]
Zander, T.; Heukamp, L.C.; Allardt Bos, M.C.; Fassunke, J.; Mattonet, C.; Merkelbach-Bruse, S.; Ko, Y.D.; Schlesinger, A.; Brockmann, M.; Serke, M.; et al. Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. J. Clin. Oncol. 2012, 30 Suppl.: Abstr. CRA10529.
[34]
The latest oncology headlines. Available online: http://ecancer.org/news/2899 (accessed on 8 August 2012).
